Women in Pharma: Looking back on 2023 and moving forward to 2024
![](/46/pdcnewsitem/12/33/75/Heading%20image%20(31).png)
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond.
As we come to the end of 2023, we look back on the successful launch of the Women in Pharma series on CPHI Online. We asked two of our previous Women in Pharma interviewees, Sanobar Syed, Business Strategy and Commercial Expert, and Helena Demuynck, Leadership Coach at oxygen4leadership, to reflect on the achievements for the pharma industry in the last year and how to continue moving forward with gender diversity and inclusivity initiatives.
1. What have been your highlights of 2023?
Syed: The year 2023 has been a rebound year for the pharmaceutical industry. We fully recovered from the COVID impact and brought resilience and our full potential back on track. In 2023, the pharmaceutical landscape witnessed a paradigm shift with the introduction of revolutionary therapies and a renewed focus on precision medicine. As a pharmaceutical professional, the highlight of the year was actively engaging in cutting-edge research and development, contributing to the launch of a groundbreaking treatment that promises to redefine patient care. The collaboration with diverse experts, the integration of artificial intelligence in analytics function, and the emphasis on sustainability within the industry marked key milestones. Navigating this dynamic environment helped me not only give tremendous exposure but also helped stay relevant and face the new year 2024 with renewed vigour and humbleness.
Demuynck: I'm thrilled to share the highlights of my journey as a transformation guide for women leaders, leveraging the empowering principles of women-centered coaching. A significant aspect of my work involves supporting successful women who, despite their professional achievements, feel stuck and yearn for fulfillment. Witnessing their transformative journeys has been an incredibly rewarding experience.
What's truly encouraging is the growing awareness among women that their voices matter, not just within corporate realms but also in their communities. We are witnessing a transformative shift in how women aspire to present themselves to the world. It's a momentous time, and I am passionate about being part of this empowering movement where women recognize their ability to make a meaningful impact, both professionally and personally. The journey ahead holds the promise of collective growth, authenticity, and a positive influence on the world. It's a pivotal moment, and the time for women to embrace their impact is now!
2. What are you looking forward on 2024?
Syed: In 2024, I'm eagerly anticipating the continued evolution of personalized medicine and the integration of advanced technologies in the analytics space. The prospect of further breakthroughs in areas like gene therapies and immunotherapy is incredibly exciting and how as a commercial analytics function, I can help build relevant solutions to the ever-changing landscape. No one solution fits all therapies, for example, the analytical solution for neuroscience will not be adequate for gene therapy. We need to understand, immerse, and truly bring ourselves in close collaboration across the teams to be able to shine and win. Additionally, I'm keeping a close eye on how the industry adapts to global health challenges and the development of more sustainable practices. It's not just about pushing scientific boundaries but also fostering a more inclusive and responsible pharmaceutical ecosystem. The journey ahead is filled with opportunities to contribute to meaningful advancements, and I'm ready to dive into the next wave of innovation and progress.
Demuynck: As an upcoming trend of 2024, I expect a powerful shift as more women are poised to recognize their capacity to make meaningful contributions, both professionally and personally. This emerging trend signals a transformative era where women are expected to redefine and assert their roles in the world. As we look forward to the trends of 2024, there is a palpable sense that women will increasingly realize the unique power and significance of their voices.
This trend will be characterized by a collective acknowledgment that women can have a substantial impact not only in corporate spheres but also in their communities. Anticipated is a growing awareness that individual voices matter, and that women are expected to make a difference beyond their professional success. It is expected to be a time of breaking through limitations, rediscovering authentic selves, and embracing purposeful living.
As women confidently step into their power, they are anticipated to contribute to a future where empowerment is not just a trend but a profound and enduring reality. The trends of 2024 represent a transformative journey where women will lead lives filled with deep fulfillment and purpose, making lasting and positive impacts in various aspects of their lives. Together, let's anticipate and embrace this shift, contributing to a world where women's empowerment continues to shape the course of progress and change.
3. What are some words of advice you would give to recent and/or upcoming graduates?
Syed: For the pharmaceutical trailblazers and generation next entering the field, I'd say: Embrace curiosity like it's your favorite lab coat or favourite software or game. The industry is dynamic and ever-changing, so keep that hunger for knowledge alive. Network, not just with your peers but also with seasoned professionals—there's a treasure trove of insights waiting for you. Attend events like CPHI which is a melting pot of knowledge, exposure and learning. Stay adaptable; be ready to pivot and learn from setbacks. And, of course, remember the impact your work can have on people's lives—it's not just about molecules, compounds, or financial revenue models, it's about making a positive difference to the patients. Oh, and one more thing: celebrate the small victories; they're the stepping stones to those big breakthroughs. You've got this!
Demuynck: My advice to recent and upcoming graduates is to recognize the unique power they possess. Embrace your voice, value your contributions, and lead with authenticity. Be resilient in the face of challenges, and remember that your journey is not defined by others' expectations. Trust in your capabilities, seek mentors, and build a community of support. The world awaits the positive influence that emerges when women lead with authenticity, purpose, and unwavering belief in their abilities.
Together, let's embark on a transformative journey, fostering a new era where women shine brightly as authentic leaders, making a lasting impact on the world.
Interested in how we're championing gender diversity and equality in the pharmaceutical industry? Click here to read all instalments of our Women in Pharma series.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development. -
News AstraZeneca to build billion-dollar ADC manufacturing site in Singapore
The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio. -
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi. -
News Racial disparities in diagnosis and drug use for dementia symptoms
A study from the USC Schaeffer Center for Health Policy & Economics has revealed the existence of racial disparities in the US for the diagnosis of dementia and the use of drug treatments for symptoms. -
News MDMA-assisted therapy for PTSD to be reviewed by US FDA
American public benefit corporation (PBC) Lykos Therapeutics have announced that the US FDA Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting their new drug application (NDA) for MDMA capsules, which are to be used in comb... -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance